Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Cardio Diagnostics Holdings Price-to-Tangible-Book Related Terms
Cardio Diagnostics Holdings Price-to-Tangible-Book Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CDIO vs LABT, ERNA, CVKD: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Cardio Diagnostics Holdings's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardio Diagnostics Holdings Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Cardio Diagnostics Holdings's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Cardio Diagnostics Holdings (CDIO) has a Price-to-Tangible-Book of 0.85 as of Sep. 04, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Cardio Diagnostics Holdings and its competitors. According to the industry distribution chart, Cardio Diagnostics Holdings ranks #103 out of 1131 companies in the Biotechnology industry, placing it in the top 9.1%.
Is Cardio Diagnostics Holdings' Price-to-Tangible-Book too high?
Cardio Diagnostics Holdings' current Price-to-Tangible-Book is 0.85. The Biotechnology industry median Price-to-Tangible-Book is 3.26. Cardio Diagnostics Holdings' value of 0.85 is 73.9% below this industry median. Based on the distribution chart, Cardio Diagnostics Holdings ranks #103 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cardio Diagnostics Holdings has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cardio Diagnostics Holdings' Price-to-Tangible-Book compare to LABT and ERNA?
According to the Biotechnology industry distribution chart, Cardio Diagnostics Holdings ranks #103 out of 1131 companies for Price-to-Tangible-Book. This places Cardio Diagnostics Holdings in the top 9% of its industry — outperforming the majority of peers. The industry median Price-to-Tangible-Book is 3.26. Cardio Diagnostics Holdings' value of 0.85 is 73.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.26, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardio Diagnostics Holdings's current Price-to-Tangible-Book of 0.85 is 73.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Cardio Diagnostics Holdings and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardio Diagnostics Holdings's current Price-to-Tangible-Book is 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardio Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings (CDIO) is currently considered Fairly Valued. The stock's GF Value™ is $1.82, compared to a current price of $1.85 — trading 1.6% above its estimated fair value. The current Price-to-Tangible-Book is 0.85 and 73.9% below the Biotechnology industry median of 3.26. Cardio Diagnostics Holdings' overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Cardio Diagnostics Holdings (CDIO), the current Price-to-Tangible-Book is 0.85 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardio Diagnostics Holdings (CDIO) Overvalued in 2026?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings stock appears to be overvalued.
The current stock price of $1.85 is trading 1.6% above its estimated GF Value™ of $1.82.
GuruFocus considers Cardio Diagnostics Holdings to be Fairly Valued.
Key valuation signals for CDIO:
Price-to-Tangible-Book: 0.85
GF Value™: $1.82 vs. price of $1.85 (1.6% above fair value)
Industry Position: 73.9% below the Biotechnology median (#103 of 1131)
No single metric tells the full story. See the CDIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
54GF Score
Get the complete analysis for CDIO
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDIO has been successfully added to your 
